Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Indo US Bio-Tech

₹210 -5.8 | 2.7%

Market Cap ₹421 Cr.

Stock P/E 51.0

P/B 6.7

Current Price ₹210

Book Value ₹ 31.3

Face Value 10

52W High ₹304

Dividend Yield 0%

52W Low ₹ 0

Indo US Bio-Tech Research see more...

Overview Inc. Year: 2004Industry: Agriculture

Indo Us Bio-Tech Ltd researches, develops, produces, markets, and sells various agricultural seeds in India. The company offers vegetable seeds, which includes tomato, okra, bottle gourd, brinjal, carrot, cluster bean, bitter gourd, ridge gourd, cucumber, cabbage, radish, sponge gourd, pepper, cold, sweet pepper, beet root, cow pea, corriander, onion, watermelon, musk melon, and flower seeds; cotton seeds; and oil seeds, along with castor, groundnut, sesamum, mustard, and soyabean seeds. It additionally provides cumin and isabgul spices seeds; pulses seeds comprising val, gram, black gram, and green gram seeds; and cereal seeds, together with wheat, maize, bajra, and pegeon pea seeds. In addition, the company engages in instructing the local farmers to cultivate the vegetation. Indo Us Bio-Tech Ltd was founded in 2004 and is based in Ahmedabad, India.

Read More..

Indo US Bio-Tech Share Price

New

| |

Volume
Price

Quarterly Price

Show Value Show %

Peer Comparison

Indo US Bio-Tech Quarterly Results

#(Fig in Cr.) Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 14 14 16 18 19 16 22 16
Other Income 0 0 0 0 0 0 0 0
Total Income 14 14 16 18 19 16 22 16
Total Expenditure 12 11 13 15 16 11 18 15
Operating Profit 2 3 2 3 3 5 4 1
Interest 0 0 0 0 0 0 0 0
Depreciation 0 1 0 0 0 3 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0
Profit Before Tax 2 2 1 3 2 2 4 1
Provision for Tax 0 0 -0 -0 0 0 0 0
Profit After Tax 2 1 1 3 2 2 4 1
Adjustments 0 0 0 -0 0 0 0 0
Profit After Adjustments 2 1 1 3 2 2 4 1
Adjusted Earnings Per Share 1 0.6 0.7 1.4 1.2 0.8 1.8 0.3

Indo US Bio-Tech Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 15 15 20 19 25 30 35 40 40 50 62 73
Other Income 0 0 0 0 0 0 0 0 0 0 0 0
Total Income 15 15 20 19 25 30 36 40 40 50 62 73
Total Expenditure 14 14 19 19 23 27 32 36 35 43 52 60
Operating Profit 1 0 1 1 1 3 3 4 6 7 9 13
Interest 0 0 0 0 1 1 0 1 1 1 1 0
Depreciation 0 0 0 0 0 0 0 0 0 0 1 3
Exceptional Income / Expenses 0 0 0 0 0 0 -0 -0 0 0 0 0
Profit Before Tax 0 0 0 0 1 2 3 3 4 5 7 9
Provision for Tax -0 -0 -0 -0 0 1 1 0 -1 0 0 0
Profit After Tax 0 0 0 0 0 1 2 3 5 5 7 9
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 0 0 0 0 0 1 2 3 5 5 7 9
Adjusted Earnings Per Share 0.4 0.3 0.5 0.4 0.4 1.4 1.4 1.7 3.5 2.9 3.6 4.1

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 24% 16% 16% 15%
Operating Profit CAGR 29% 31% 25% 25%
PAT CAGR 40% 33% 48% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 102% 143% 37% NA%
ROE Average 16% 20% 20% 19%
ROCE Average 15% 16% 17% 15%

Indo US Bio-Tech Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 2 2 3 3 3 5 14 16 22 39 54
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 1 1 1 3 3 2
Other Non-Current Liabilities -0 -0 -0 -1 -0 0 1 1 1 1 0
Total Current Liabilities 4 4 4 10 9 10 9 17 18 12 12
Total Liabilities 6 6 7 13 12 17 24 35 43 55 69
Fixed Assets 1 1 1 1 1 2 1 1 2 6 7
Other Non-Current Assets 0 0 0 0 0 0 1 1 3 3 2
Total Current Assets 5 5 6 12 11 15 21 32 38 47 60
Total Assets 6 6 7 13 12 17 24 35 43 55 69

Indo US Bio-Tech Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 0 0 0 0 0 0 0 0 0 0 0
Cash Flow from Operating Activities -1 0 0 -3 0 -1 -3 -1 0 3 1
Cash Flow from Investing Activities -0 -0 -0 -0 -0 0 -3 -1 -2 -5 -7
Cash Flow from Financing Activities 1 -0 0 3 0 1 6 2 1 2 6
Net Cash Inflow / Outflow -0 0 0 0 -0 0 0 0 -0 -0 0
Closing Cash & Cash Equivalent 0 0 0 0 0 0 0 0 0 0 0

Indo US Bio-Tech Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 0.36 0.32 0.48 0.35 0.39 1.41 1.43 1.74 3.5 2.86 3.61
CEPS(Rs) 0.48 0.43 0.59 0.49 0.53 1.56 1.6 1.89 3.67 3.09 4.02
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 2.24 2.56 2.82 3.17 3.4 4.81 9.52 11.27 14.78 21.21 27.18
Core EBITDA Margin(%) 3.37 2.46 3.1 2.66 5.06 9.11 9.64 9.97 13.75 13.85 15.21
EBIT Margin(%) 2.79 2.19 2.96 2.43 4.73 9.32 9.03 9.43 13.24 13.37 13.91
Pre Tax Margin(%) 1.41 0.74 1.3 1.26 2.13 6.89 7.92 7.2 10.29 10.97 11.96
PAT Margin (%) 2.01 1.75 2.53 1.89 1.62 4.89 5.88 6.37 12.72 10.46 11.73
Cash Profit Margin (%) 2.62 2.36 3.12 2.62 2.22 5.41 6.56 6.91 13.34 11.31 13.06
ROA(%) 4.85 4.33 7.63 3.55 3.14 10.01 10.26 8.66 13.05 10.63 11.67
ROE(%) 16.29 13.19 19.83 11.69 11.74 34.36 22.21 16.74 26.87 17.34 15.51
ROCE(%) 11.89 8.96 13.92 7.39 14.24 27.84 20.35 16.65 18.3 15.86 14.62
Receivable days 77.13 63.33 30.8 66.23 79.35 86.57 92.79 137.87 207.92 164.93 133.85
Inventory Days 44.02 48 57.87 90.52 77.96 69.85 86.98 91.16 95.73 128.48 148.59
Payable days 58.34 55.86 46.8 86.01 79.05 63.91 54.15 418.37 0 -222.52 302.49
PER(x) 0 0 0 0 0 0 24.41 12.29 3.87 11.81 29.43
Price/Book(x) 0 0 0 0 0 0 3.68 1.9 0.92 1.59 3.91
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.19 0.19 0.16 0.32 0.26 0.33 1.61 0.99 0.78 1.48 3.64
EV/Core EBITDA(x) 5.62 6.81 4.57 10.08 4.82 3.39 16.56 9.96 5.6 10.45 23.84
Net Sales Growth(%) 0 -0.85 32.22 -2.69 28.66 20.85 19.82 12.03 0.82 24.86 23.36
EBIT Growth(%) 0 -22.24 78.43 -20.1 150.63 138.15 16.12 16.89 41.59 26.1 28.35
PAT Growth(%) 0 -13.29 91.02 -27.42 10.06 265.83 44.11 21.38 101.13 2.73 38.25
EPS Growth(%) 0 -13.29 52.53 -27.42 10.06 265.83 1.66 21.38 101.13 -18.39 26.4
Debt/Equity(x) 0.91 0.78 0.58 1.44 1.39 1.32 0.45 0.52 0.53 0.32 0.21
Current Ratio(x) 1.23 1.21 1.41 1.18 1.27 1.47 2.45 1.91 2.12 3.85 4.87
Quick Ratio(x) 0.82 0.68 0.46 0.65 0.67 0.87 1.21 1.36 1.46 1.94 2.68
Interest Cover(x) 2.02 1.51 1.78 2.08 1.82 3.83 8.1 4.24 4.5 5.57 7.15
Total Debt/Mcap(x) 0 0 0 0 0 0 0.12 0.28 0.58 0.2 0.05

Indo US Bio-Tech Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 73.01 73.01 73.01 74.02 70.17 70.17 70.17 70.17 70.17 70.17
FII 0 0 0 0 0 0 0 0 0 0
DII 0 0 0 0 0 0 0 0 0 0
Public 26.99 26.99 26.99 25.98 29.83 29.83 29.83 29.83 29.83 29.83
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 47% CAGR over last 5 years
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Debtor days have increased from -222.52 to 302.49days.
  • Stock is trading at 6.7 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Indo US Bio-Tech News

Top Unlisted Companies & InstaBuy Companies

Sell or Purchase Share (Tentative Price)

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....